IATDMCT Congress 2017 Poster Presentations

To get the latest update, please clear or refresh your web browser's cache.
*i.e. Google Chrome: Ctr + F5 keys

P25-1: Anti-infective drugs (1): Aminoglycosides and betalactams

# Presentation Title Name Country Affiliation
1 Population pharmacokinetic modeling approach to compare differentamikacin dose rates in children with cystic fibrosis: Are we efficientenough? Jean-BaptisteWoillard France CHU Limoges, Univ Limoges
2 The effect of gentamicin peak concentration based dosing on gentamicintarget attainment in critically ill patients Reinier van Hest TheNetherlands Academic Medical Center
3 Tobramycin toxicity after use of antibiotic loaded cement Penny D.Colbourne Canada University of Alberta Hospital
4 External evaluation of amikacin population pharmacokinetic models inJapanese adult patients Ken-ichi Sako Japan Nihon Pharmaceutical University
5 A high performance liquid chromatography method for the determinationof doripenem in human plasma and dialysate Sirin Phenphinan Thailand Khon Kaen University
6 Do prolonged infusions of imipenem protect against the effects ofaugmented renal clearance and obesity? Jan Strojil Czech Republic Palacky University Olomouc
7 A cohort study of therapeutic drug monitoring on Meropenem in ICUpatients Lu Jin China Nanjing Drum Tower Hospital, AffiliatedHospital of Nanjing University, The MedicalSchool
8 Highly variable absorption of clavulanic acid during the day: a populationpharmacokinetic analysis Femke de Velde TheNetherlands Erasmus MC
9 PROSAB Study: Concentration of cefazolin and ciprofloxacin in prostatetissue Erik Wilms TheNetherlands Central Hospital Pharmacy The Hague

P25-2: Anti-infective drugs (2): Beta-lactams

# Presentation Title Name Country Affiliation
1 An UHPLC-HR-MS assay for beta-lactams in bronchoalveolar lava fluid Alain GastonVerstraete Belgium Ghent University Hospital and GhentUniversity
2 Development of novel LCMSMS assay for therapeutic drug monitoring offive beta-lactam antibiotics in human plasma Edwin Zhi WeiTing Singapore Shimadzu (Asia Pacific) Pte Ltd.
3 Simultaneous determination of nine beta-lactam antibiotics in humanplasma by an ultrafast hydrophilic-interaction chromatography ? tandemmass spectrometry Birgit C. P. Koch TheNetherlands Erasmus MC
4 Tandem LC-MS/MS method for the determination of Piperacillin (PIP) andTazobactam (TAZ) in human plasma of patients in intensive care units whoare critically ill: pitfalls and potential solutions Carsten Mueller Germany University Hospital of Cologne
5 The SPIT study: correlation of saliva and plasma beta-lactam antibioticconcentrations in the intensive care unit Sofie Colman Belgium Ghent University Hospital
6 Population pharmacokinetic analysis of piperacillin and tazobactam byusing their blood and urine level data in Japanese pediatric patients Noriyuki Ishihara Japan Shimane University Hospital
7 Pharmacokinetic and pharmacodynamic characterization of piperacillin-tazobactam, flomoxef and pazufloxacin in prostate issue and plasma ofprostatic hypertrophy patients Akira Kuroda Japan Hiroshima University
8 Broad spectrum beta-lactam antibiotic levels in critically ill Asian patients Lawrence Soon-ULee Singapore National University of Singapore
9 Tonic clonic generalized seizure in 6 years old boy in association withprocaine penicillin injection: a variant of Hoigne's syndrome? Hundie Tesfaye Czech Republic University Hospital Motol, CharlesUniversity

P25-3: Anti-infective drugs (3): TB drugs

# Presentation Title Name Country Affiliation
1 A proposal of an individualized dosage regimen of isoniazid in tuberculosispatients Karim Aouam Tunisia University of Monastir
2 Population pharmacokinetics of isoniazid in Tunisian tuberculosis patientsbased on routinely data Karim Aouam Tunisia University of Monastir
3 Adequacy of isoniazid and rifampicin in anti-tuberculosis treatment inchildren; a pharmacometric approach Blessed WinstonAruldhas India Christian Medical College, Vellore
4 A case report of rifampicin content in a red bezoar, which was found in apatient who took rifampicin for the treatment of pulmonarymycobacterium avium complex MasamiKawahara Japan Kanazawa Municipal Hospital
5 Development and validation of anti-TB drugs in plasma and tissue tosupport pharmacokinetic-driven studies Mark A. Marzinke United States ofAmerica Johns Hopkins University
6 Meta-analysis of NAT2 genotypes and the risk for anti-tuberculosisinduced liver injury (AT-DILI) SupharatSuvichapanich Japan University of Tokyo
7 Pharmacokinetic and pharmacodynamic characterization of piperacillin-tazobactam, flomoxef and pazufloxacin in prostate issue and plasma ofprostatic hypertrophy patients Akira Kuroda Japan Hiroshima University

P25-4: Anti-infective drugs (4): Vancomycin

# Presentation Title Name Country Affiliation
1 Vancomycin PBPK modeling in special populations to elucidate case-basedclinical PK observations Chie Emoto United States ofAmerica Cincinnati Children's Hospital MedicalCenter
2 Vancomycin trough concentrations alone might not be an accuratesurrogate for AUC in clinical practice Hana Suchankova Czech Republic Palacky University Olomouc
3 Comparison of outcome of vancomycin by using different monitoringtechniques between AUC/MIC and trough concentration in Thaipopulation PakwanBunupuradah Thailand Ramathibodi Hospital, Mahidol University
4 Population pharmacokinetic analysis of vancomycin in patients withhematopoietic stem cell transplantation Akira Okada Japan Kobe Gakuin University
5 Optimizing vancomycin dosage with a therapeutic drug monitoringprogram in thrice-weekly hemodialysis patients Patricio Mas-Serrano Spain Hospital General Universitario de Alicante
6 Large prediction errors of vancomycin simulation in ICU patients Michiya Akabane Japan Shiga University of Medical ScienceHospital
7 Usefulness of the Bayesian estimation based TDM for vancomycin doseindividualization in patients with continuous renal replacement therapy Kazutaka Oda Japan Kumamoto University Hospital
8 Therapeutic drug monitoring of vancomycin based on an HPLC method Yi Zhou China The First Affiliated Hospital of ChongqingMedical University
9 HPLC method for determination of vankomycin in cerebrospinal fluid Eva Klapkova Czech Republic Charles University and University HospitalMotol
10 Vancomycin and the true value Eva Hoess Germany Roche Diagnostics GmbH

P25-5: Anti-infective drugs (5)

# Presentation Title Name Country Affiliation
1 Development of an immunoassay-based point-of-care testing (POCT)device for therapeutic drug monitoring of vancomycin Koichiro Tsuchiya Japan Tokushima University
2 Combined dried blood spot analysis of vancomycin, tobramycin andcreatinine using LC-MS/MS for monitoring outpatient parenteralantimicrobial therapy Evelien terWeijden TheNetherlands University Medical Center Utrecht
3 Vancomycin-induced nephrotoxicity in mice Masaki Takigawa Japan Tokyo Metropolitan Geriatric Hospital
4 Pharmacokinetics of intrathecal administration of vancomycin in patientswith infectious meningitis Milada Halacova Czech Republic Na Homolce Hospital
5 An evaluation of the effectivity of the current treatment of uncomplicatedurinary tract infections with fosfomycin based on urinary concentrations inhealthy volunteers Rixt Anna Wijma TheNetherlands Erasmus MC
6 AUC/MIC ratio used for therapeutic drug monitoring of levofloxacin afterfour different regimens MatthieuGregoire France University Hospital of Nantes
7 Antimicrobial resistance pattern in a block primary health centre in India Preeti Barnwal India Jamia Hamdard

P25-6: Immunosuppressive drugs (1): LC-MS/MS assay

# Presentation Title Name Country Affiliation
1 Comparison of PETINIA and LC-MS/MS for determining plasmamycophenolic acid concentrations in Japanese lung transplant recipients Masafumi Kikuchi Japan Tohoku University Hospital
2 A validated UPLC-MS/MS method for intracellular tacrolimusconcentrations Brenda C. M. deWinter TheNetherlands Erasmus MC
3 An 8 second analytical method for Tacrolimus in whole blood by LDTD-MS/MS Kamisha L.Johnson-Davis United States ofAmerica University of Utah Health Sciences Centerand ARUP Institute for Clinical andExperimental Pathology
4 UHPLC-MS/MS based determination of cyclosporine A, tacrolimus andeverolimus in autologous serum eye drops for the treatment of ocularmanifestation of GvHD in patients following allogeneic hematopoietic Martin HelgeJosef Wiesen Germany University of Cologne
5 Fully automated platform for sensitive determination ofimmunosuppressant drugs in whole blood using high quality internalstandardization Eishi Imoto Japan Shimadzu Corporation
6 Simultaneous determination of 6-thioguanine nucleotides and 6-methylmercaptopurine in the red blood cells of patients with Crohn'sdisease by HPLC-DAD Xuemei Luo China Nanjing Drum Tower Hospital, The AffliatedNanjing University Medical School
7 Automated sample preparation of whole blood - the need for speed Miguel GambellBarroso Sweden Karolinska University Laboratory
8 Pharmacokinetics and pharmacodynamics of tacrolimus into its target cellsfor the longitudinal follow up of liver transplant recipients: looking for newbiomarkers for therapeutic drug monitoring Camille Tron France Rennes University Hospital
9 Investigation of tacrolimus transport mechanisms into the white bloodcells: Does only P-glycoprotein matter? Camille Tron France Rennes University Hospital

P25-7: Immunosuppressive drugs (2): Monoclonal antibody and genotyping

# Presentation Title Name Country Affiliation
1 Quantification of active infliximab in human serum with LC-MS/MS Mohsin El Amrani TheNetherlands University Medical Center Utrecht
2 Determination of belatacept pharmacokinetics in renal transplant patientsusing a novel automated assay Rolf AntonKlaasen Norway Oslo University Hospital
3 Intra-patient variability in the pharmacokinetics of etanerceptmaintenance treatment Teun van Gelder TheNetherlands Erasmus MC
4 A novel application for antibody quantitation method development andvalidation of infliximab in plasma by nSMOL and Skyline software Song Yuling China Shimadzu (China) CO., LTD.
5 Assay development toward Infliximab therapeutic monitoring by LCMS:new strategy using CDR-peptide selective proteolysis nSMOL Takashi Shimada Japan Shimadzu Corporation
6 TDM of infliximab by LC-MS/MS using nSMOL in patients withinflammatory bowel disease Atsushi Yonezawa Japan Kyoto University Hospital
7 Therapeutic drug monitoring in inflammatory bowel disease- a preliminaryreport from india Alpa J. Dherai India P.D. Hinduja National Hospital and MedicalResearch Centre
8 Influence of combined CYP3A4 and CYP3A5 single-nucleotidepolymorphisms on tacrolimus exposure in kidney transplant recipients Karim Aouam Tunisia University of Monastir
9 Allele and genotype frequencies of the cytochrome P450 genes CYP3A*1B,CYP3A4*22 and CYP3A5*3 in the Tunisian population Karim Aouam Tunisia University of Monastir
10 Allele frequency of thiopurine-S-methyltransferase (TPMT) and inosinetriphosphate pyrophosphatase (ITPA) genes in the Tunisian population Karim Aouam Tunisia University of Monastir

P25-8: Immunosuppressive drugs (3): Biomarkers and pharmacokinetics

# Presentation Title Name Country Affiliation
1 Does the CYP3A biomarker 4beta-hydroxycholesterol predict tacrolimusdose early after kidney transplantation? Elisabet Storset Norway Oslo University Hospital
2 Monitoring plasmatic miRNA-155-5p expression as biomarker of prognosisof acute rejection in liver transplant recipients Olga Millan Spain Hospital Clinic of Barcelona, University ofBarcelona
3 Pharmacokinetic of tacrolimus in Mexican adult patients with renaltransplant: population analysis with NONMEM Silvia Romano Mexico Universidad Autonoma de San Luis Potosi
4 The regulatory effects of tacrolimus- and sirolimus-basedimmunosuppressive regimens on Tfh and Tfr cells in kidney transplantrecipients Ya-Mei Li China West China Hospital of Sichuan University
5 Regulation of cellular and soluble Tim-3 in renal transplant recipientstreated with sirolimus- or tacrolimus-based immunosuppressive regimens Ya-Mei Li China West China Hospital of Sichuan University
6 Additional value of CYP3A5 status in a tacrolimus populationpharmacokinetic model used for therapeutic drug monitoring Jean-BaptisteWoillard France CHU Limoges, Univ Limoges
7 Development of parametric and non-parametric population models andbayesian estimators for Envarsus tacrolimus formulation in livertransplantation Jean-BaptisteWoillard France CHU Limoges, Univ Limoges
8 No influence of CYP3A5*3 and CYP3A4*22 on regain of CYP3A phenotypeafter kidney transplantation Kristine Hole Norway Diakonhjemmet Hospital
9 FP7 BIOMARGIN preliminary results of the investigation of a small set ofurinary peptides to diagnose antibody mediated rejection Jean-BaptisteWoillard France CHU Limoges Univ Limoges
10 Drug-drug interaction risk assessment using PBPK modeling: inhibitorymagnitude of diltiazem and its metabolite on sirolimus disposition Chie Emoto United States ofAmerica Cincinnati Children's Hospital MedicalCenter

P25-9: Oncologic drugs (1)

# Presentation Title Name Country Affiliation
1 Dried plasma spot analysis for gefitinib, erlotinib, afatinib and osimertinibusing high performance liquid chromatography tandem massspectrometry Reiko AndoMakihara Japan National Cancer Center Hospital
2 Development and validation of a method for the determination ofpaclitaxel in human plasma by high performance liquid chromatographywith diode array detection Marina VenzonAntunes Brazil Universidade Feevale
3 Quantification of hydroxyurea in human plasma by HPLC-MS/MS and itsapplication to pharmacokinetics in patients with chronic myeloidleukaemia Xin Hai China The First Affiliated Hospital of HarbinMedical University
4 Quantification method for immune check point inhibitor, Nivolumab, usingliquid chromatography tandem mass spectrometry Irie Kei Japan Institute of Biomedical Research andInnovation
5 Simultaneous quantification of 5-FU, uracil and tegafur using ultra-performance liquid chromatography coupled to tandem massspectrometry Ken Shiraiwa Japan Oita University Hospital
6 New effective and sensitive method for quantification of tamoxifen, N-desmethyl tamoxifen, 4-hydroxy tamoxifen and endoxifen in humanplasma Gerd Ackehed Sweden Karolinska University Laboratory
7 Quantification of total Dinutuximab in neuroblastoma patients with LC-MS/MS Mohsin El Amrani TheNetherlands University Medical Center Utrecht
8 LC-MS/MS analysis of 5-fluorouracil in plasma for clinical research Stephen Balloch United Kingdom Waters Corporation
9 UPLC-MS/MS analysis of plasma busulfan for clinical research Gareth Hammond United Kingdom Waters Corporation
10 Utility of therapeutic drug monitoring of sunitinib in patients withmetastatic Renal Cell Carcinoma Vikram Gota India ACTREC, Tata Memorial Centre

P25-10: Oncologic drugs (2)

# Presentation Title Name Country Affiliation
1 Retrospective investigation of concomitant medications as potential riskfactors for sever neutropenia in cancer patients treated with carboplatinand paclitaxel combination therapy Yurie Katsube Japan Kyoto Pharmaceutical University
2 Molecular cornifing mechanisms of multi-targeted tyrosine kinaseinhibitors-induced hand-foot skin reaction based on genetic differences ofSTAT3 KazuhiroYamamoto Japan Kobe University Hospital
3 To explore the clinical toxicology of intravesical chemotherapy for patientswith non-invasive bladder cancer: a population-based analysis of bladdercancer in Taiwan Min-Chia Wang Taiwan Chi Mei Medical Center
4 Voriconazole dosing strategies in young children: challenges andrecommendations FerdiSombogaard TheNetherlands VU University Medical Center Amsterdam
5 Open-label randomized study of individualized pharmacokinetically (PK)-guided dosing versus body surface area (BSA) dosing of paclitaxel (PTX) inadvanced non-small cell lung cancer (NSCLC) NCT02058433 Salvatore JosephSalamone United States ofAmerica Saladax Biomedical, Inc.
6 Prohibitin 1, potential predictive marker of oxaliplatin response ofcolorectal cancer cells Kanako Hara Japan Keio University
7 Preclinical and clinical studies on establishment of invasive marker ofdihydropyrimidine dehydrogenase activity and its usefulness in 5-fluorouracil-based chemotherapy Yukako Ito Japan Kyoto Pharmaceutical University
8 Impact of STAT3 genetic polymorphism on sunitinib-induced stomatitis inJapanese renal cell carcinoma patients Aimi Watanabe Japan Doshisha Women's College of Liberal Arts
9 Loss of tumor suppressor CYLD sensitizes oral squamous cell carcinomacells to EGFR-TKI Satoru Shinriki Japan Kumamoto University
10 A role of genetic polymorphisms in genes related to sunitinib and SU12662clearance NorikoMatsunaga Japan Nagasaki University Hospital

P25-11: Clinical toxicology (1)

# Presentation Title Name Country Affiliation
1 In vitro monoamine oxidase inhibition potential of new psychoactivesubstances of the alpha-methyltryptamine type Lea Wagmann Germany Saarland University
2 Mitigation of lung toxicity induced by B(a)P via modulation of oxidativestress and inflammation by carvacrol in mice Preeti Barnwal India Jamia Hamdard
3 Amelioration of radiation-induced hematological and biochemicalalterations in Swiss albino mice by vernonia cinerea extract Nitin Verma India Baddi University of Emerging Sciences &Technology
4 New psychoactive substances: in vitro metabolism studies using humanliver preparations compared to primary human hepatocytes and humanurine Lilian H. J. Richter Germany Saarland University
5 Protective role of Sildenafil against carbon tetrachloride-inducednephrotoxicity by augmenting the availability of nitric oxide andantioxidant enzymes Shubham Goyal India Baddi University of Emerging Sciences &Technology
6 In vitro human metabolism of the synthetic cannabinoid 5F-PY-PINACA HidenobuKawashima Japan Gifu Pharmaceutical University and GifuPrefectural Research Institute for Healthand Environmental Sciences
7 Evaluation of toxicological risk due to the presence of bisphenol A inthermal papers Marina VenzonAntunes Brazil Universidade Feevale
8 In vitro treatment of induced pluripotent stem cells with retinoic acid forthe placental drug transport evaluation model Yuka Kawasaki Japan Osaka Ohtani University
9 Effectiveness of fresh frozen plasma in management of acuteorganophosphate intoxicated patients: an updated systematic review andmeta-analysis Ola Elsayed Nafea Egypt Zagazig University